Which patients with locally advanced cervical cancer would you consider as candidates for moderately hypofractionated pelvic chemoradiation before brachytherapy?

At present, would not offer outside clinical trials, as data are limited, with some suggesting a higher risk of acute morbidity also. Doses of EBRT in these studies are also not similar, varying from 37.5 in 15, 40 in 16, 44 in 20, and 43.3 in 17.